What is HC Wainwright’s Forecast for VolitionRx Q1 Earnings?

VolitionRx Limited (NYSE:VNRX) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of VolitionRx in a report issued on Tuesday, April 8th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for VolitionRx’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.04) EPS and FY2026 earnings at $0.01 EPS.

A number of other research analysts also recently weighed in on VNRX. StockNews.com started coverage on VolitionRx in a research note on Saturday, April 5th. They set a “sell” rating on the stock. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, VolitionRx currently has a consensus rating of “Hold” and an average target price of $3.33.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.48 on Wednesday. VolitionRx has a 52 week low of $0.42 and a 52 week high of $1.02. The firm’s fifty day moving average is $0.57 and its 200-day moving average is $0.63. The firm has a market cap of $48.76 million, a P/E ratio of -1.34 and a beta of 1.15.

Insider Activity at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the acquisition, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. The trade was a 8.59 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC bought a new stake in VolitionRx during the fourth quarter worth about $36,000. Lagoda Investment Management L.P. lifted its holdings in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. Northern Trust Corp boosted its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the 4th quarter valued at $29,000. Finally, Geode Capital Management LLC lifted its stake in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.